Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$329.59 -0.6%	$353.07	$261.43 ▼ $391.29	$179.01B	0.44	2.67 million shs	1.92 million shs
LLY Eli Lilly and Company	$965.85 +1.8%	$941.13	$623.78 ▼ $1,133.95	$893.19B	0.48	3.47 million shs	3.51 million shs
NVO Novo Nordisk A/S	$46.34 +0.6%	$39.05	$35.12 ▼ $81.44	$205.70B	0.77	18.76 million shs	17.76 million shs
PFE Pfizer	$25.82 +0.5%	$27.09	$21.97 ▼ $28.75	$146.36B	0.35	36.64 million shs	43.47 million shs

The 7 Hottest IPOs On Wall Street’s 2026 Watchlist

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	-0.64%	-0.07%	-6.08%	-9.61%	+23.97%
LLY Eli Lilly and Company	+1.88%	+0.07%	+2.77%	-5.78%	+31.19%
NVO Novo Nordisk A/S	+0.69%	+5.68%	+23.50%	-5.52%	-29.53%
PFE Pfizer	+0.67%	-1.99%	-4.03%	-6.48%	+15.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$329.59 -0.6%	$353.07	$261.43 ▼ $391.29	$179.01B	0.44	2.67 million shs	1.92 million shs
LLY Eli Lilly and Company	$965.85 +1.8%	$941.13	$623.78 ▼ $1,133.95	$893.19B	0.48	3.47 million shs	3.51 million shs
NVO Novo Nordisk A/S	$46.34 +0.6%	$39.05	$35.12 ▼ $81.44	$205.70B	0.77	18.76 million shs	17.76 million shs
PFE Pfizer	$25.82 +0.5%	$27.09	$21.97 ▼ $28.75	$146.36B	0.35	36.64 million shs	43.47 million shs

The 7 Hottest IPOs On Wall Street’s 2026 Watchlist

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	-0.64%	-0.07%	-6.08%	-9.61%	+23.97%
LLY Eli Lilly and Company	+1.88%	+0.07%	+2.77%	-5.78%	+31.19%
NVO Novo Nordisk A/S	+0.69%	+5.68%	+23.50%	-5.52%	-29.53%
PFE Pfizer	+0.67%	-1.99%	-4.03%	-6.48%	+15.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.48	Hold	$357.12	8.35% Upside
LLY Eli Lilly and Company	2.87	Moderate Buy	$1,218.33	26.14% Upside
NVO Novo Nordisk A/S	2.13	Hold	$65.56	41.50% Upside
PFE Pfizer	2.23	Hold	$28.74	11.30% Upside

Current Analyst Ratings Breakdown

Latest LLY, NVO, PFE, and AMGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/7/2026	AMGN Amgen	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/7/2026	LLY Eli Lilly and Company	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target		$880.00 ➝ $900.00
5/6/2026	PFE Pfizer	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
5/5/2026	AMGN Amgen	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/5/2026	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$1,183.00
5/4/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
5/4/2026	AMGN Amgen	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$351.00 ➝ $340.00
5/4/2026	LLY Eli Lilly and Company	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$1,325.00
5/4/2026	LLY Eli Lilly and Company	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1,350.00 ➝ $1,400.00
5/1/2026	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$1,344.00
5/1/2026	AMGN Amgen	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$332.00

(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$36.75B	4.84	$33.60 per share	9.81	$16.08 per share	20.50
LLY Eli Lilly and Company	$65.18B	13.96	$25.60 per share	37.73	$28.07 per share	34.41
NVO Novo Nordisk A/S	$46.80B	4.42	$4.71 per share	9.83	$6.58 per share	7.04
PFE Pfizer	$62.58B	2.35	$4.42 per share	5.84	$15.26 per share	1.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$7.71B	$14.37	22.94	14.03	3.33	20.96%	137.41%	13.28%	N/A
LLY Eli Lilly and Company	$20.64B	$28.15	34.31	21.82	1.03	34.98%	105.77%	23.76%	N/A
NVO Novo Nordisk A/S	$15.51B	$4.26	10.88	13.63	4.14	37.23%	63.31%	22.19%	N/A
PFE Pfizer	$7.77B	$1.31	19.71	9.03	N/A	11.83%	19.44%	8.41%	N/A

Latest LLY, NVO, PFE, and AMGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2026	Q1 2026	NVO Novo Nordisk A/S	$0.87	$1.04	+$0.17	$1.69	$10.86 billion	$10.85 billion
5/5/2026	Q1 2026	PFE Pfizer	$0.7220	$0.75	+$0.0280	$0.47	$13.84 billion	$14.45 billion
4/30/2026	Q1 2026	AMGN Amgen	$4.77	$5.15	+$0.38	$3.34	$8.58 billion	$8.62 billion
4/30/2026	Q1 2026	LLY Eli Lilly and Company	$6.97	$8.55	+$1.58	$8.26	$17.82 billion	$19.80 billion
3/31/2026	Q1 2026	NVO Novo Nordisk A/S	N/A	$1.0270	N/A	$1.69	N/A	$10.85 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$10.08	3.06%	+8.27%	70.15%	14 Years
LLY Eli Lilly and Company	$6.92	0.72%	+15.18%	24.58%	11 Years
NVO Novo Nordisk A/S	$1.75	3.78%	+21.74%	41.08%	N/A
PFE Pfizer	$1.72	6.66%	-13.20%	131.30%	16 Years

Latest LLY, NVO, PFE, and AMGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/22/2026	PFE Pfizer	quarterly	$0.43	6.71%	5/8/2026	5/8/2026	6/12/2026
5/4/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.72%	5/15/2026	5/15/2026	6/10/2026
3/4/2026	AMGN Amgen	quarterly	$2.52	2.66%	5/15/2026	5/15/2026	6/5/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	5.65	1.26	1.01
LLY Eli Lilly and Company	1.26	1.50	1.10
NVO Novo Nordisk A/S	0.59	0.79	0.56
PFE Pfizer	0.67	1.25	0.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.85%
LLY Eli Lilly and Company	0.14%
NVO Novo Nordisk A/S	0.07%
PFE Pfizer	0.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	31,500	539.68 million	535.10 million	Optionable
LLY Eli Lilly and Company	50,000	941.74 million	940.42 million	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable
PFE Pfizer	75,000	5.70 billion	5.66 billion	Optionable

LLY, NVO, PFE, and AMGN Headlines

Recent News About These Companies

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

7 minutes ago | globenewswire.com

Is Pfizer a Buy, Sell, or Hold in 2026?

16 minutes ago | fool.com

Pfizer's Net Income Drops in Q1. Is Its Dividend Still Safe?

1 hour ago | finance.yahoo.com

Pfizer's Net Income Drops in Q1. Is Its Dividend Still Safe?

1 hour ago | fool.com

Is This a Sign Pfizer's Aggressive Growth Strategy Is Paying Off?

May 11 at 6:49 PM | fool.com

Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

May 11 at 10:53 AM | 247wallst.com

Is Most-Watched Stock Pfizer Inc. (PFE) Worth Betting on Now?

May 11 at 10:01 AM | zacks.com

Pfizer vs Eli Lilly: Different Bets on Pharma M&A

May 11 at 9:10 AM | 247wallst.com

Pfizer vs Eli Lilly: Different Bets on Pharma M&A

May 11 at 9:05 AM | 247wallst.com

Pfizer Inc. $PFE Shares Purchased by Swiss Life Asset Management Ltd

May 11 at 7:32 AM | marketbeat.com

Pfizer Inc. $PFE Shares Sold by Kepler Cheuvreux Suisse SA

May 11 at 6:33 AM | marketbeat.com

Securian Asset Management Inc. Sells 119,974 Shares of Pfizer Inc. $PFE

May 11 at 6:24 AM | marketbeat.com

49,073 Shares in Pfizer Inc. $PFE Bought by Manning & Napier Advisors LLC

May 11 at 5:49 AM | marketbeat.com

Erste Group Bank Increases Earnings Estimates for Pfizer

May 11 at 1:54 AM | americanbankingnews.com

FY2027 EPS Estimates for Pfizer Boosted by Erste Group Bank

May 11 at 1:54 AM | marketbeat.com

Pfizer Advances Oncology Portfolio While Extending Vyndamax Cash Flow Visibility

May 10 at 2:14 PM | finance.yahoo.com

Could Buying This Beaten-Down Healthcare Stock Make You Rich If It Recovers?

May 9 at 12:15 PM | fool.com

Pfizer Juggles Cancer Setbacks and Lyme Vaccine Push

May 9 at 11:11 AM | tipranks.com

F m Investments LLC Has $7.39 Million Holdings in Pfizer Inc. $PFE

May 9 at 4:34 AM | marketbeat.com

Cheviot Value Management LLC Boosts Position in Pfizer Inc. $PFE

May 9 at 4:23 AM | marketbeat.com

Here is Why Pfizer (PFE) One of the Best High Volume Stocks to Invest In

May 9 at 3:50 AM | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LLY, NVO, PFE, and AMGN Company Descriptions

Amgen NASDAQ:AMGN

$329.59 -2.11 (-0.64%)

Closing price 05/11/2026 04:00 PM Eastern

Extended Trading

$331.50 +1.91 (+0.58%)

As of 07:05 AM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Eli Lilly and Company NYSE:LLY

$965.85 +17.40 (+1.83%)

Closing price 05/11/2026 03:59 PM Eastern

Extended Trading

$970.02 +4.17 (+0.43%)

As of 07:07 AM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S NYSE:NVO

$46.34 +0.27 (+0.58%)

Closing price 05/11/2026 03:59 PM Eastern

Extended Trading

$47.38 +1.05 (+2.26%)

As of 07:07 AM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Pfizer NYSE:PFE

$25.82 +0.14 (+0.55%)

Closing price 05/11/2026 03:59 PM Eastern

Extended Trading

$25.83 +0.01 (+0.05%)

As of 07:07 AM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LLY, NVO, PFE, and AMGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LLY, NVO, PFE, and AMGN Earnings

Compare Dividends

Latest LLY, NVO, PFE, and AMGN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LLY, NVO, PFE, and AMGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LLY, NVO, PFE, and AMGN Company Descriptions

Amgen NASDAQ:AMGN

Eli Lilly and Company NYSE:LLY

Novo Nordisk A/S NYSE:NVO

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools